Paying users zone. Data is covered by hidden.

  • Get to Biogen Inc. for $15.99, or

  • get to whole website for at least 3 months from $49.99.

Microsoft Excel LibreOffice Calc


Enterprise Value to FCFF (EV/FCFF)

Difficulty: Intermediate


Free Cash Flow to The Firm (FCFF)

Biogen Inc., FCFF calculation

USD $ in thousands

Microsoft Excel LibreOffice Calc
12 months ended Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Net income attributable to Biogen Inc. hidden hidden hidden hidden hidden
Net (income) loss attributable to noncontrolling interests, net of tax hidden hidden hidden hidden hidden
Net noncash charges hidden hidden hidden hidden hidden
Changes in operating assets and liabilities, net hidden hidden hidden hidden hidden
Net cash flows provided by operating activities hidden hidden hidden hidden hidden
Cash paid during the year for interest, net of tax1 hidden hidden hidden hidden hidden
Capitalized interest costs related to construction in progress, net of tax2 hidden hidden hidden hidden hidden
Purchases of property, plant and equipment hidden hidden hidden hidden hidden
Acquisitions of intangible assets hidden hidden hidden hidden hidden
Free cash flow to the firm (FCFF) hidden hidden hidden hidden hidden

Based on: 10-K (filing date: 2018-02-01), 10-K (filing date: 2017-02-02), 10-K (filing date: 2016-02-03), 10-K (filing date: 2015-02-04), 10-K (filing date: 2014-02-06).

Item Description The company
FCFF Free cash flow to the firm is the cash flow available to the Biogen Inc.'s suppliers of capital after all operating expenses have been paid and necessary investments in working and fixed capital have been made. Biogen Inc.'s FCFF increased from 2015 to 2016 but then declined significantly from 2016 to 2017.

Interest Paid, Net of Tax

Biogen Inc., interest paid, net of tax calculation

USD $ in thousands

Microsoft Excel LibreOffice Calc
12 months ended Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Effective Income Tax Rate (EITR)
EITR1 hidden hidden hidden hidden hidden
Interest Paid, Net of Tax
Cash paid during the year for interest, before tax hidden hidden hidden hidden hidden
Less: Cash paid during the year for interest, tax2 hidden hidden hidden hidden hidden
Cash paid during the year for interest, net of tax hidden hidden hidden hidden hidden
Interest Costs Capitalized, Net of Tax
Capitalized interest costs related to construction in progress, before tax hidden hidden hidden hidden hidden
Less: Capitalized interest costs related to construction in progress, tax3 hidden hidden hidden hidden hidden
Capitalized interest costs related to construction in progress, net of tax hidden hidden hidden hidden hidden

Based on: 10-K (filing date: 2018-02-01), 10-K (filing date: 2017-02-02), 10-K (filing date: 2016-02-03), 10-K (filing date: 2015-02-04), 10-K (filing date: 2014-02-06).

2017 Calculations

2 Cash paid during the year for interest, tax = Cash paid during the year for interest × EITR
= hidden × hidden = hidden

3 Capitalized interest costs related to construction in progress, tax = Capitalized interest costs related to construction in progress × EITR
= hidden × hidden = hidden


Enterprise Value to FCFF Ratio, Current

Biogen Inc., current EV/FCFF calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Selected Financial Data (USD $ in thousands)
Enterprise value (EV) hidden
Free cash flow to the firm (FCFF) hidden
Ratio
EV/FCFF hidden
Benchmarks
EV/FCFF, Competitors
Abbott Laboratories hidden
AbbVie Inc. hidden
Allergan PLC hidden
Amgen Inc. hidden
Bristol-Myers Squibb Co. hidden
Celgene Corp. hidden
Eli Lilly & Co. hidden
Gilead Sciences Inc. hidden
Johnson & Johnson hidden
Merck & Co. Inc. hidden
Pfizer Inc. hidden
Regeneron Pharmaceuticals Inc. hidden
EV/FCFF, Sector
Pharmaceuticals & Biotechnology hidden
EV/FCFF, Industry
Health Care hidden

Based on: 10-K (filing date: 2018-02-01).

If company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.

Otherwise, if company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.


Enterprise Value to FCFF Ratio, Historical

Biogen Inc., historical EV/FCFF calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in thousands)
Enterprise value (EV)1 hidden hidden hidden hidden hidden
Free cash flow to the firm (FCFF)2 hidden hidden hidden hidden hidden
Ratio
EV/FCFF3 hidden hidden hidden hidden hidden
Benchmarks
EV/FCFF, Competitors
Abbott Laboratories hidden hidden hidden hidden hidden
AbbVie Inc. hidden hidden hidden hidden hidden
Allergan PLC hidden hidden hidden hidden hidden
Amgen Inc. hidden hidden hidden hidden hidden
Bristol-Myers Squibb Co. hidden hidden hidden hidden hidden
Celgene Corp. hidden hidden hidden hidden hidden
Eli Lilly & Co. hidden hidden hidden hidden hidden
Gilead Sciences Inc. hidden hidden hidden hidden hidden
Johnson & Johnson hidden hidden hidden hidden hidden
Merck & Co. Inc. hidden hidden hidden hidden hidden
Pfizer Inc. hidden hidden hidden hidden hidden
Regeneron Pharmaceuticals Inc. hidden hidden hidden hidden hidden
EV/FCFF, Sector
Pharmaceuticals & Biotechnology hidden hidden hidden hidden hidden
EV/FCFF, Industry
Health Care hidden hidden hidden hidden hidden

Based on: 10-K (filing date: 2018-02-01), 10-K (filing date: 2017-02-02), 10-K (filing date: 2016-02-03), 10-K (filing date: 2015-02-04), 10-K (filing date: 2014-02-06).

2017 Calculations

3 EV/FCFF = EV ÷ FCFF
= hidden ÷ hidden = hidden

Ratio Description The company
EV/FCFF Enterprise value to free cash flow to the firm is whole company valuation indicator. Biogen Inc.'s EV/FCFF ratio declined from 2015 to 2016 but then increased from 2016 to 2017 exceeding 2015 level.